Concepedia

Jakub Krejcik

JK

Statistics

Publications

13

Citations

2.7K

H-Index

11

Active since

2013

Affiliations

Vejle Sygehus(Current)

Janssen (United States)

University of Southern Denmark

University Medical Center Utrecht

Dana-Farber Cancer Institute

Jakub Krejcik is an author at Vejle Sygehus specializing in immunotherapy, cancer immunotherapy, and medicine.

Publications per year

2013–2018

13

Publications

13

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof et al. · Blood · 2016 · 918 citations · Full text

Life Sciences, Immunology, Oncology +17

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof et al. · Clinical Cancer Research · 2017 · 171 citations

Medicine, Immunology, Pharmacology +15

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Homer Adams, Frederik Stevenaert, Jakub Krejcik et al. · Cytometry Part A · 2018 · 160 citations · Full text

Medicine, Immunology, Pharmacology +16

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Torben Plesner, Hendrik‐Tobias Arkenau, Peter Gimsing et al. · Blood · 2016 · 110 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

1–5 of 13